Globus Medical Reports 5.9% Revenue Growth to $789.6 Million in Q2 2026

Globus Medical, Inc. reported a notable increase in financial performance for the second quarter of 2026, with net sales reaching $789.6 million, a 5.9% increase from $745.3 million in the same period last year. For the first half of 2026, the company achieved total net sales of $1.55 billion, up 15.3% from $1.34 billion in the first half of 2025. The increase in revenue was primarily driven by a 12.8% rise in U.S. sales, totaling $1.22 billion, and a significant 25.8% increase in international sales, which amounted to $325.5 million.

The company's operating income for the second quarter was $182.4 million, compared to $76.1 million in the prior year, reflecting a substantial improvement in profitability. However, net income for the quarter decreased to $151.6 million from $202.8 million year-over-year, largely due to a lack of the previous year's one-time bargain purchase gain of $110.6 million related to the Nevro Merger. The effective income tax rate for the quarter was 20.1%, a significant increase from a negative 7.8% in the prior year, attributed to a one-time tax benefit in the previous period.

Operationally, Globus Medical has made strategic advancements, including the acquisition of certain patents related to medical device technology for $1.5 million and the continued integration of Nevro Corp. following its merger in April 2025. The company has also focused on expanding its product offerings, particularly in the Musculoskeletal Solutions segment, which saw sales increase by $45.7 million, driven by higher sales of spine implantable devices and neuromonitoring services. The Enabling Technologies segment, however, experienced a decline in sales, which the company aims to address through enhanced product adoption and market penetration.

As of June 30, 2026, Globus Medical reported total assets of $5.49 billion, an increase from $5.30 billion at the end of 2025. The company’s cash and cash equivalents stood at $507.7 million, down from $526.2 million at the end of the previous year. The total equity increased to $4.77 billion, reflecting strong retained earnings growth. The company continues to focus on expanding its sales force and enhancing its international presence, with plans to increase its market share in both existing and new markets.

Looking ahead, Globus Medical remains optimistic about its growth trajectory, emphasizing its commitment to innovation in medical devices and expanding its product portfolio. The company anticipates continued revenue growth driven by increased adoption of its Musculoskeletal Solutions and Enabling Technologies, alongside strategic investments in research and development. However, management acknowledges potential risks, including market competition and economic conditions, which could impact future performance.